Soil-based organism (SBO) probiotics are probiotic preparations containing bacterial strains — primarily Bacillus species such as Bacillus subtilis, Bacillus coagulans, Bacillus clausii, and Bacillus licheniformis — that are naturally found in soil and the environment. The concept behind SBO probiotics is rooted in the hygiene hypothesis: pre-industrial humans consumed these spore-forming bacteria regularly through contact with soil and unprocessed food, and their reduction in modern diets and environments may contribute to dysbiosis and immune dysregulation.
The key distinguishing feature of Bacillus-based SBO probiotics is their ability to form endospores — dormant, heat-resistant, acid-resistant protective shells that allow the bacteria to survive the harsh conditions of stomach acid and upper GI transit that kill a significant proportion of conventional Lactobacillus and Bifidobacterium strains before they reach the colon. This is a real and meaningful advantage in terms of viable organism delivery.
Survival through the stomach: Standard Lactobacillus strains are vulnerable to gastric acid and bile salts. Depending on the product, anywhere from 10% to 90% of CFUs may be dead before reaching the colon. Bacillus spores survive this transit reliably, germinating once they reach the more neutral environment of the small intestine and colon.
Stability: Lactobacillus-based probiotics typically require refrigeration to maintain viability. SBO spore-formers are shelf-stable at room temperature for extended periods — a practical advantage.
Colonisation pattern: Lactobacillus and Bifidobacterium strains are generally transient inhabitants — they do not permanently colonise the colon and their effects cease with supplementation. Bacillus species may have a longer residence time and interact with the resident microbiome in a different way, potentially stimulating greater diversity through quorum sensing and competitive exclusion of pathogenic bacteria.
Immune modulation: Bacillus subtilis produces a range of antimicrobial compounds (iturin, surfactin, fengycin) and has demonstrated immunomodulatory effects including stimulation of secretory IgA production and modulation of Th1/Th2 balance. These effects may be distinct from those of Lactobacillus strains.
The evidence base for SBO probiotics is genuinely growing, though smaller than for established Lactobacillus and Bifidobacterium strains that have been studied for decades. The most clinically studied individual strain is Bacillus coagulans.
A 2015 RCT by Majeed et al. (Journal of Gastroenterology and Hepatology) found that B. coagulans MTCC 5856 (LactoSpore®) at 2 billion spores daily significantly improved IBS symptoms (abdominal pain, bloating, stool consistency) compared to placebo over 90 days. A 2018 meta-analysis of B. coagulans trials across multiple GI conditions found consistent, statistically significant improvements in symptom scores.
Bacillus clausii has the strongest evidence for antibiotic-associated diarrhoea, with a 2005 Cochrane-reviewed RCT in children demonstrating reduced duration of acute diarrhoea. B. subtilis PXN21 has been studied in healthy adults and shown significant improvements in GI symptoms and wellbeing scores.
| Claim | Evidence Level | Source |
|---|---|---|
| Superior GI tract survival vs standard Lactobacillus | Strong (mechanism) | Spore-forming biology; multiple in vitro survival studies |
| Reduces IBS symptoms | Moderate | Majeed et al. 2015 RCT; 2018 meta-analysis (B. coagulans) |
| Reduces antibiotic-associated diarrhoea | Moderate | B. clausii RCTs; Nista et al. 2004 |
| Improves gut microbiome diversity | Limited | Small studies; consistent directional effect |
| Superior to Lactobacillus for all gut conditions | Not Established | Different strains for different conditions; not head-to-head evidence |
Small intestinal bacterial overgrowth (SIBO) is a condition in which bacteria — normally limited to the colon — populate the small intestine in excessive numbers, causing gas, bloating, diarrhoea, and malabsorption. SIBO is increasingly recognised as an underlying driver of symptoms labelled as IBS.
Both SBO and standard probiotics can potentially worsen SIBO in susceptible individuals. If you have SIBO (diagnosed via breath testing), introducing additional live bacteria — including spore-forming SBOs — into a small intestine that is already bacterially overloaded may aggravate symptoms. Several case reports and clinical observations support this concern, though controlled data is limited. Anyone with suspected or diagnosed SIBO should discuss probiotic use with a practitioner experienced in SIBO management before starting any probiotic.
SBO probiotic products vary widely in their strain composition and spore count. Products typically contain 1–10 billion spores per serving of one or more Bacillus strains. They can be taken with or without food and do not require refrigeration. Starting with a lower dose and building up over 2–4 weeks can minimise initial bloating.
Bacillus species in probiotic products have an excellent safety record in healthy adults and children. Unlike some pathogens in the Bacillus genus (e.g., B. cereus causing food poisoning), probiotic strains are selected for documented safety. However, immunocompromised individuals and those with central venous catheters should exercise caution — there are rare case reports of Bacillus bacteraemia in severely immunosuppressed patients from probiotic-grade strains.
SBO probiotics offer real biological advantages over many Lactobacillus-based products in terms of GI survival, stability, and immune interaction. The clinical evidence, while smaller in total volume, is credible and growing. They are a legitimate alternative or complement to standard probiotic preparations, particularly for those who have found conventional probiotics ineffective. The SIBO warning is important and should inform the choice to use any probiotic in people with relevant symptoms. Strain matters significantly — look for products specifying B. coagulans, B. subtilis, or B. clausii with documented spore counts.